Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9098
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYadi Permana, Muhammad-
dc.contributor.authorSarwanti, Sarwanti-
dc.contributor.authorFauziah, Siti-
dc.date.accessioned2024-12-16T03:31:29Z-
dc.date.available2024-12-16T03:31:29Z-
dc.date.issued2023-10-01-
dc.identifier.issn2338-2732-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/9098-
dc.description.abstractABSTRACT Breast cancer is among the deadliest gynecology cancers in the world. However, the management of advancedstage breast cancer is often harder as a result of chemoresistance. This review aimed to discover the effect of bromocriptine on prolactin-positive breast cancer patients who received anthracycline-based chemotherapy. It is known that anthracycline works by inhibiting topoisomerase IIα (TOP2A), forming free radicals, binding DNA, and altering cell homeostasis, hence stopping the cell cycle and inducing cell death. However, reduction of TOP2A expression and increased glutathione s-transferase (GST) and ATP-binding cassette (ATP) membrane activity increase anthracycline efflux from the cell membrane, hence reducing its effectivity. Prolactin is one of the most common chemoresistance agents whose complex with its receptor will induce JAK/STAT pathway to increase GST. The regulation of Bcl-2 and ERK was also determined by prolactin. Bromocriptine is an agonist of the D2 dopamine receptor that inhibits adenyl cyclase and a D1 dopamine weak antagonist. Bromocriptine could reduce prolactin serum and receptors in various cases. Some studies have found that bromocriptine could improve the effectiveness of chemotherapy regimens, including cancer-related hyperprolactinemia, breast cancer that underwent cisplatin, and taxanes. Therefore, bromocriptine offers potential as it could improve outcomes and reduce resistance in prolactin-positive breast cancer patients who are administered anthracycline-based neoadjuvant chemotherapy. Keywords: breast cancer, bromocriptine, chemotherapy, prolactin, receptoren_US
dc.language.isoenen_US
dc.publisherPerhimpunan Dokter Spesialis Penyakit dalam Indonesiaen_US
dc.subjectbreast cancer,en_US
dc.subjectbromocriptine,en_US
dc.subjectchemotherapy,en_US
dc.subjectprolactin,en_US
dc.subjectreceptoren_US
dc.titleEffectivity of Bromocriptine Administration Towards Prolactin Positive Breast Cancer Receiving Anthracycline-Based Chemotherapy: A Literature Reviewen_US
dc.typeArticleen_US
Appears in Collections:VOL 55 NO 4 2023

Files in This Item:
File Description SizeFormat 
465-474.pdf935.19 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.